Clinical Trial Update: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE [Phase 3]

View source ↗

Summary

Phase 3 trial assessing once-daily versus twice-daily budesonide orodispersible tablets for induction of remission in eosinophilic esophagitis, currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• budesonide orodispersible tablets (budesonide)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: RECRUITING